Publications by authors named "J L Alderfer"
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Am J Clin Dermatol
July 2024
Background: Abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is efficacious in moderate-to-severe atopic dermatitis with a manageable long-term safety profile.
Objective: We aimed to provide updated integrated long-term safety results for abrocitinib from available data accrued up to a maximum of almost 4 years in patients with moderate-to-severe atopic dermatitis from the JADE clinical development program.
Methods: Analysis included 3802 patients (exposure: 5213.
Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden.
Objectives: The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]).
We examine how and why Americans have experienced interrupted health care during the COVID-19 pandemic and measure awareness and usage of expanded benefits offered by health insurers and employers. We use an expanded concept of health literacy to include knowledge of access conditions and consider if patients' knowledge of the health system may relate to utilization of care. We conducted an online survey of 451 U.
View Article and Find Full Text PDFArticle Synopsis
- Patients often switch back from generic medications to brand-name ones, despite generics being bioequivalent and cheaper, with initial analysis suggesting a lower switchback rate for authorized generics (AGs) compared to other generics.
- The study utilized the Pharmetrics Plus™ database to analyze switching patterns and costs related to brand medications and their generics from 2007 to 2019, focusing on patients who started on brand meds before generic availability.
- Results indicated that while over half of patients switched to generics, the switchback rates to brand medications were similar between those who used AGs and those who used other generics, with a noticeable tendency towards increased medical costs leading up to switchbacks, though this wasn't consistent for
Article Synopsis
- The study evaluated how American perceptions of health issues have evolved over time and assessed which problems they believe should receive more research funding.
- The researchers conducted a survey with 768 participants, asking them to rate 80 health issues' seriousness and prioritize 20 for research support.
- Results showed that serious health concerns include leading causes of death like heart disease and diabetes, but also emphasize social determinants of health, with COVID-19 and cancer being top priorities for research funding.